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Abstract
With the support of ESCMID and European countries, EUCAST has developed a disk diffusion test with zone diameter breakpoints
correlated with the EUCAST clinical MIC breakpoints. The development of the EUCAST disk diffusion method and quality control criteria
are described, together with guidance on quality control and implementation of the method in clinical microbiology laboratories. The
method includes the use of Mueller–Hinton agar without supplements for non-fastidious organisms and with 5% mechanically deﬁbrinated
horse blood and 20 mg/L b-NAD for fastidious organisms, a standardized inoculum resulting in conﬂuent growth, an incubation time of 16–
20 h, a reading guide on how to read zone diameters on individual species-agent combinations and zone diameter breakpoints calibrated to
the EUCAST clinical MIC breakpoints. EUCAST recommendations are described in detail and updated regularly on the EUCAST website
(http://www.eucast.org).
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Introduction
Disk diffusion is one of the oldest approaches to antimicrobial
susceptibility testing (AST) and remains one of the most widely
used AST methods in routine clinical microbiology laborato-
ries. The method is versatile in that it is suitable for testing the
majority of bacterial pathogens, including the more common
fastidious bacteria, almost all antimicrobial agents can be tested
and it requires no special equipment. When performed
according to recommendations, disk diffusion is a reproducible
and accurate method for AST [1,2]. Several of the European
national antimicrobial breakpoint committees, including BSAC
in the UK [3], CA-SFM in France [4], DIN in Germany [5] and
SRGA in Sweden [6], developed their own disk diffusion
methods for AST, but there was no common method
calibrated to European breakpoints. Following the harmoniza-
tion of European MIC breakpoints [7] by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST),
the committee initiated the development of a standardized
disk diffusion method calibrated to the harmonized MIC
breakpoints. In common with most other disk diffusion
techniques, the EUCAST method is based on the principles
deﬁned in the report of the International Collaborative Study
of Antimicrobial Susceptibility Testing [8] and on the experi-
ence of expert groups worldwide.
The need for a standardized disk diffusion method cali-
brated to EUCAST clinical MIC breakpoints became obvious
from responses to a questionnaire sent by EUCAST to
EUCAST European national representatives in 2007. The
questionnaire responses indicated that the disk diffusion
methods used most widely included Mueller–Hinton (MH)
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agar with an inoculum corresponding to a McFarland 0.5
turbidity standard, as described by Bauer et al. [9]. Many
laboratories followed the performance standards published by
the United States Clinical and Laboratory Standards Institute
(CLSI) [10,11] or local modiﬁcations of the CLSI method. The
opinions expressed in the questionnaire strongly supported
the development of a European disk diffusion method, based
on the widely used Kirby–Bauer method [9] and calibrated to
EUCAST clinical MIC breakpoints. It was also evident that a
common medium for fastidious organisms instead of separate
media for Streptococcus spp. and Haemophilus inﬂuenzae would
facilitate laboratory work. In response to these demands,
EUCAST, in collaboration with and ﬁnanced by The European
Society for Clinical Microbiology and Infectious Diseases
(ESCMID), developed a standardized disk diffusion method
based on MH agar with an inoculum density equivalent to a
McFarland 0.5 standard and with the speciﬁc aim to develop a
common medium for fastidious organisms. These objectives
have been achieved and zone diameter breakpoints calibrated
to the EUCAST clinical MIC breakpoints have been established
by analysis of MIC-zone diameter correlations, inhibition zone
diameter distributions and MIC distributions. This paper
describes the development and calibration of the disk diffusion
method, how quality control targets and ranges were devel-
oped and validated, and presents guidance on how to
implement the EUCAST disk diffusion method in the routine
laboratory.
Basic Materials and Methodology
The following description of the EUCAST disk diffusion
methodology is a summary of the methodology detailed in a
manual on the EUCAST website [12]. The ﬁrst version of the
manual was released in December 2009 and it is updated
annually. The described technique must be adhered to without
modiﬁcation in order to obtain reliable results. Tables
including organisms covered by the EUCAST disk diffusion
method, and corresponding methodology recommendations
for each of these, are available in the EUCAST disk diffusion
test manual and, from 2014, will also be in a table on the ﬁrst
page of the EUCAST breakpoint tables.
Preparation of media
Unsupplemented MH agar is used for non-fastidious organisms
and MH agar supplemented with 5% (v/v) mechanically
deﬁbrinated horse blood and 20 mg/L b-NAD (‘Mueller–
Hinton fastidious’, MH-F) for fastidious organisms. MH agar is
prepared according to the manufacturer’s instructions and
supplements are added after cooling to 42–45°C. Agar is
dispensed in Petri dishes to achieve an even depth of 4.0 mm
with a maximum variation of 0.5 mm.
Preparation of inoculum
The inoculum suspension is prepared by selecting several
morphologically similar colonies (when possible) from over-
night growth (16–24 h of incubation) on a non-selective
medium with a sterile loop or a cotton swab and suspending
the colonies in sterile saline (0.85% NaCl w/v in water) to the
density of a McFarland 0.5 standard, approximately corre-
sponding to 1–2 9 108 CFU/mL for Escherichia coli. The
density of the suspension is preferably measured with a
photometric device that has been calibrated with a McFarland
standard according to the manufacturer’s instructions. Alter-
natively, the density of the suspension can be compared
visually to a 0.5 McFarland turbidity standard. The density of
the suspension is adjusted to McFarland 0.5 by addition of
saline or more organisms. Streptococcus pneumoniae is prefer-
ably suspended from colonies on a blood agar plate to the
density of a McFarland 0.5 standard. When S. pneumoniae is
suspended from colonies on a chocolate agar plate, the
inoculum must be equivalent to a McFarland 1.0 standard in
order to contain a sufﬁcient number of viable cells. All
inoculum suspensions should optimally be used within 15 min
and always within 60 min of preparation.
Inoculation of agar plates
A sterile cotton swab is dipped into the inoculum suspension
and the excess ﬂuid removed by turning the swab against the
inside of the tube to avoid over-inoculation of plates,
particularly for Gram-negative organisms. The inoculum is
spread evenly over the entire surface of the agar plate by
swabbing in three directions or by using an automatic plate
rotator.
Application of antimicrobial disks
Antimicrobial disks should be handled and stored according to
the manufacturer’s instructions. Disks are applied ﬁrmly on the
agar surface within 15 min of inoculation of the plates. It is
important that zone diameters can be reliably measured and
the maximum number of disks on a plate depends on the size
of the plate, the organism and the antimicrobial agents tested.
The number of disks on a plate should be limited so that
unacceptable overlapping of zones is avoided. A maximum of
six disks can be accommodated on a 90-mm circular plate and
12 on a 150-mm circular plate.
Incubation of plates
Within 15 min of application of antimicrobial disks, the plates
are inverted and incubated at 35  1°C for 16–20 h, unless
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otherwise stated in the disk diffusion test manual on the
EUCAST website [12]. Unsupplemented MH agar plates are
incubated in air and MH-F agar plates in 5  1% CO2 in air.
The efﬁciency of incubators varies so appropriate numbers of
plates in stacks should be determined as part of the
laboratory’s quality assurance programme. Small stacks of
plates with a space between stacks are more likely to ensure
uniform and rapid heating of all plates.
Examination of plates after incubation
A correct inoculum and satisfactorily streaked plates should
result in an even conﬂuent lawn of growth. If individual
colonies can be seen, the inoculum is too light and the test
should be repeated. The age of the culture, the nutritional
requirements of the strains or failure to comply with
recommendations should be considered before retesting. If
zone edges are jagged, the evenness of streaking of the plate
should be improved.
Measurement of inhibition zone diameters and interpretation
of results
After incubation, inhibition zones are read at the point where
no obvious growth is detected by the unaided eye when the
plate is held about 30 cm from the eye. The inhibition zone
diameters are measured to the nearest millimetre with a ruler,
calliper or an automated zone reader. Unsupplemented MH
agar plates are read from the back of the plate with reﬂected
light against a dark background whereas MH-F agar plates are
read from the front with the lid removed and with reﬂected
light. For haemolytic streptococci on MH-F agar plates,
inhibition of growth and not inhibition of haemolysis should
be read. If double zones are visible, the inner zone should be
read, unless otherwise speciﬁcally stated. Speciﬁc reading
instructions are given in the EUCAST disk diffusion test manual
[12] and in the EUCAST reading guide [13]. Zone diameters
are interpreted and categorized as susceptible, intermediate or
resistant according to the EUCAST clinical breakpoint tables
[14].
Quality control
Deﬁned control strains (Table 1) are used to monitor test
performance. For antimicrobial agents that are part of routine
panels, control tests should optimally be set up daily. In
addition to the daily routine quality control tests, each new
batch of MH agar (i.e. a different batch (new lot) of agar
powder or a switch in the manufacturer of agar for
in-house-produced plates or each new shipment of commer-
cial pre-poured plates) should be tested to ensure that all
zones are within the acceptable ranges deﬁned in the EUCAST
routine quality control tables [15].
Development of Methodology
Medium
Mueller–Hinton medium is the only generic, commercially
available medium for AST and it has been recommended by the
CLSI and CA-SFM for more than 25 years. Many laboratories
and manufacturers of pre-poured plates have long traditions
and extensive knowledge of production and use of MH media.
MH was therefore the obvious choice for EUCAST when
deciding on the medium. However, there is some variation in
MH from different manufacturers and between batches from
the same manufacturer. Some of this variation (e.g. cation
content) affects antimicrobial activity and some affects the
growth of the bacteria, which in turn may affect the size of
inhibition zones, and each new batch of MH agar must be
quality controlled to ensure that inhibition zones are within
EUCAST ranges.
Development of MH-F medium
For fastidious organisms EUCAST did not want to recom-
mend different media for different organisms. We aimed to
develop a common medium for H. inﬂuenzae, S. pneumoniae,
streptococcus groups A, B, C and G, viridans group strepto-
TABLE 1. Strains recommended by EUCAST for routine
quality control
Organism Strain collection number Characteristics
Escherichia coli ATCC 25922 Susceptible, wild type
NCTC 12241
CIP 76.24
DSM 1103
CCUG 17620
CECT 434
Pseudomonas
aeruginosa
ATCC 27853 Susceptible, wild type
NCTC 12903
CIP 76.110
DSM 1117
CCUG 17619
CECT 108
Staphylococcus
aureus
ATCC 29213 Weak b-lactamase
producerNCTC 12973
CIP 103429
DSM 2569
CCUG 15915
CECT 794
Enterococcus
faecalis
ATCC 29212 Susceptible, wild type
NCTC 12697
CIP 103214
DSM 2570
CCUG 9997
CECT 795
Streptococcus
pneumoniae
ATCC 49619 Low-level, chromosomally
mediated penicillin resistantNCTC 12977
CIP 104340
DSM 11967
CCUG 33638
Haemophilus
inﬂuenzae
NCTC 8468 Susceptible, wild type
CIP 54.94
CCUG 23946
ATCC, American Type Culture Collection, USA; NCTC, National Collection of
Type Cultures, UK; CIP, Collection de Institut Pasteur, France; DSM, Deutsche
Stammsammlung f€ur Mikroorganismen und Zellkulturen, Germany; CCUG, The
Culture Collection University of Gothenburg, Sweden; CECT, Coleccion Espa~nola
de Cultivos Tipo, Spain.
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cocci, Campylobacter spp., Pasteurella multocida, Listeria mono-
cytogenes, Corynebacterium spp., Neisseria spp. and rapidly
growing anaerobes. National antimicrobial breakpoint com-
mittees have previously developed or adopted different media
for fastidious organisms. The CLSI [10] and CA-SFM [4]
recommend MH agar supplemented with 5% sheep blood for
streptococci and Haemophilus Test Medium (HTM) for
H. inﬂuenzae. The BSAC [3] and SRGA [6] have both
recommended Iso-Sensitest agar (Thermo Fisher Ltd, Basing-
stoke, UK) supplemented with 5% mechanically deﬁbrinated
horse blood and 20 mg/L b-NAD. We exchanged the
Iso-Sensitest agar for MH agar and found that this medium,
named ‘Mueller–Hinton fastidious’ (Mueller–Hinton agar with
5% deﬁbrinated horse blood and 20 mg/L b-NAD, MH-F),
supports good growth of most of the fastidious organisms
listed above, including H. inﬂuenzae (21st European Congress
of Clinical Microbiology and Infectious Diseases (ECCMID),
poster 749; 22nd ECCMID, posters 671, 676 and 682).
However, MH-F has been shown to be inadequate for growth
of Neisseria gonorrhoeae and anaerobes.
MH-F agar was compared with a similar medium where
sheep blood was used instead of horse blood. However, with
sheep blood the growth of H. inﬂuenzae was inadequate unless
the concentration of b-NAD was increased at least ﬁve-fold (to
100 mg/L), which would signiﬁcantly increase the cost of the
medium. At a concentration of 20 mg/L in MH-F agar, b-NAD
from seven different manufacturers [Acros (Fair Lawn, NJ,
USA), BDH (VWR International, Radnor, PA, USA), Biomol
(Hamburg, Germany), Fluka (Sigma-Aldrich, Steinheim, Ger-
many), ICN Biomedicals (Irvine, CA, USA), Merck (Whitehouse
station, CA, USA) and Sigma-Aldrich resulted in good and very
similar growth of H. inﬂuenzaeNCTC 8468 and inhibition zone
diameters were within1 mm for all investigated antimicrobial
agents, including b-lactam agents, tetracyclines and trimetho-
prim-sulphamethoxazole. Concentrations of b-NAD as low as
10 mg/L supported good growth and resulted in reliable
inhibition zone diameters for H. inﬂuenzae and S. pneumoniae,
but 20 mg/L b-NAD was selected for MH-F medium to allow
for some variation in purity, quality and concentration between
manufacturers.
MH-F plates prepared at the EUCAST Laboratory for
Antimicrobial Susceptibility Testing (V€axj€o, Sweden) between
2009 and 2012 using a total of 11 different batches of MH agar
from four manufacturers (Oxoid, Bio-Rad, BBL and bioMerie-
ux) and more than 150 batches of deﬁbrinated horse blood
have shown reproducible inhibition zones for S. pneumoniae
ATCC 49619 and H. inﬂuenzae NCTC 8468 over time, with
random variation within the quality control ranges similar to
that for other organisms and agents on unsupplemented MH
agar (Fig. 1).
Inoculum preparation, inoculation of plates and application of
disks
The preparation and handling of inoculum suspensions, inocu-
lated plates and antimicrobial disks affect the size of inhibition
zone diameters in disk diffusion tests and therefore require
careful standardization. EUCAST recommends that the inocu-
lum suspension should optimally be used within 15 and always
within 60 min of preparation to ensure the correct number of
viable cells. Numbers of colony forming units in suspensions of
overnight cultures of E. coli ATCC 25922, S. pneumoniae ATCC
49619 andH. inﬂuenzaeNCTC8468 adjusted to the density of a
McFarland 0.5 turbidity standard were shown to be within the
recommended range (1–2 9 108 CFU/mL) when left at ambi-
ent temperature (20–22°C) for 15 and 60 min. However, the
effect of leaving the inoculum suspension at ambient tempera-
ture for more than 15 min has not been investigated for all
organisms and we strongly recommend that the inoculum
suspension is used within 15 min. Disks should be placed on
inoculated plates within 15 min and then placed in the correct
incubation atmosphere within another 15 min. If inoculated
plates are left at room temperature for longer periods of time
before the disks are applied, the organisms may begin to grow
prior to disk application, resulting in erroneous reduction in
sizes of inhibition zones. When inoculated plates were left at
room temperature for 2 h before application of disks, inhibition
zone diameters for E. coli ATCC 25922 and Staphylococcus
aureus ATCC 29213 (with 9 and 11 antimicrobial agents,
respectively, representing different classes of antimicrobial
agents) were 1–3 mm smaller compared with when disks were
applied immediately. Systematic accumulation of such deviations
will signiﬁcantly affect the results and can contribute to
misinterpretation of susceptibility testing results. Furthermore,
if the plates are left at room temperature for longer than 15 min
after disks have been applied, pre-diffusion may result in
erroneously large zones of inhibition.
Incubation of plates
Unless otherwise stated in the EUCAST disk diffusion test
manual [12], plates are incubated at 35  1°C for 16–20 h.
MH plates are incubated in air and MH-F plates in 5% CO2.
Repeated reading of inhibition zones of quality control strains
after 16, 18 and 20 h incubation, respectively, yielded inhibi-
tion zone diameters that varied randomly within 1 mm for
each antimicrobial agent tested (with 6–11 antimicrobial
agents, depending on the strain, representing different classes
of agents). However, prolonging incubation beyond 20 h
resulted in growth of colonies within the inhibition zones for
some organism-agent combinations. Incubation beyond 20 h is
permitted only for species and/or antimicrobial agents for
which a longer incubation has been validated (e.g. for
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FIG. 1. Examples of reproducibility of inhibition zones over time for quality control strains. Strains were routinely tested on in-house prepared MH
and MH-F plates (212 and 125 batches, respectively, including 11 different batches of MH agar from four manufacturers). For each strain-agent
combination, the inhibition zone was read once daily. Altogether, 15 laboratory technicians were involved in setting up and reading tests. Thick black
lines show EUCAST QC limits. (a) S. aureus ATCC 29213 with erythromycin 15 lg disk on MH agar (n = 697 with eight zone diameters (1.1%) out
of range). (b) S. pneumoniae ATCC 49619 with erythromycin 15 lg disk on MH-F agar (n = 707 with 16 zone diameters (2.3%) out of range). (c)
S. aureus ATCC 29213 with rifampicin 5 lg disk on MH agar (n = 695 with 12 zone diameters (1.7%) out of range). (d) S. pneumoniae ATCC 49619
with rifampicin 5 lg disk on MH-F agar (n = 704 with 29 zone diameters (4.1%) out of range). (e) S. aureus ATCC 29213 with
trimethoprim-sulphamethoxazole 25 lg disk on MH agar (n = 674 with 37 zone diameters (5.5%) out of range). (f) S. pneumoniae ATCC 49619
with trimethoprim-sulphamethoxazole 25 lg disk on MH-F agar (n = 705 with seven zone diameters (1.0%) out of range).
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Campylobacter jejuni and coli with all agents and for enterococci
with glycopeptides).
Reading of zones
In any disk diffusion test, the reading of zones is the most
difﬁcult variable to standardize. Reading of zones includes
measuring the zone diameter, inspecting the zone edge and the
detection of colonies within the inhibition zone. For some
organism-agent combinations (e.g. S. aureus and benzylpenicil-
lin) a sharp zone edge indicates the presence, and for others
(e.g. enterococci and vancomycin) the absence, of a resistance
mechanism. Excluding contamination, the presence of growth
within a zone may be due to resistance, but for some
organism-agent combinations is typical for susceptible strains
(e.g. Stenotrophomonas maltophilia with trimethoprim-sulpha-
methoxazole). In order to improve standardization of reading,
EUCAST has published reading guidelines in the EUCAST disk
diffusion test manual [12] and illustrative pictures in the
EUCAST reading guide [13].
Accuracy and Reproducibility
Validation of accuracy using available quality control criteria
The technical aspects of the EUCAST [12] and theCLSI [10] disk
diffusion methodologies are almost identical for non-fastidious
organisms and EUCAST has checked and then adopted several
of the quality control strains and the criteria recommended by
CLSI. There is a small difference in the standard incubation time,
16–18 h in the CLSI method and 16–20 h in the EUCAST
method, and for a few agents EUCAST recommends lower disk
contents than CLSI (Table 2). In order to validate materials and
testing conditions used for the EUCAST disk diffusion test,
inhibition zones for CLSI quality control strains, E. coli ATCC
25922, Pseudomonas aeruginosa ATCC 27853 and S. aureus
ATCC 25923, were generated using CLSI disk contents.
Repeated testing was performed with a total of ﬁve different
batches of MH agar from three manufacturers (two batches
fromOxoid, two from BBL and one from bioMerieux) and disks
fromOxoid. For each recommended CLSI zone diameter range,
a median value was calculated (the ‘CLSI target’). The measured
mean inhibition zone diameters were compared with the ‘CLSI
targets’. All mean values were within 2 mm of the ‘CLSI
targets’, with the majority being within 1 mm (Table 3).
As part of the validation of materials and testing conditions
(as described above), tests to establish control ranges were
performed for (i) S. aureus ATCC 29213 and E. faecalis ATCC
29212 on MH, (ii) S. pneumoniae ATCC 49619 and H. inﬂuen-
zae NCTC 8468 on MH-F, (iii) additional antimicrobial agents
and (iv) agents with a different disk content to CLSI (EUCAST
disk content). All other test characteristics were identical to
those used for the CLSI control strains. From these tests,
EUCAST quality control ranges were calculated as described in
the section on establishment of EUCAST quality control
ranges (see below). Batches of MH agar from additional
manufacturers (Bio-Rad, MAST and Lioﬁlchem) were subse-
quently tested when available. Disks from one or more
additional manufacturer (BD, Bio-Rad, I2a, Lioﬁlchem, MAST,
Oxoid and Rosco) were tested if there was a difference of
>1 mm between CLSI and EUCAST results.
Reproducibility
The reproducibility of the EUCAST disk diffusion test was
investigated by analysis of data for quality control strains and
data for clinical isolates tested between 2009 and 2012 at the
Department of Clinical Microbiology, V€axj€o Central Hospital,
Sweden, which was the ﬁrst laboratory where the EUCAST
methodology was implemented. A total of 212 and 125 in-house
prepared batches of MH and MH-F agar plates, respectively,
(including a total of 11 different batches of MH agar from four
manufacturers) were used in routine antimicrobial susceptibility
TABLE 2. Differences in disk content between EUCAST and
CLSI disk diffusion methods
Antimicrobial agenta EUCAST disk content CLSI disk content
Benzylpenicillin 1 unit 10 units
Ampicillin 2 and 10 lgb 10 lg
Amoxicillin-clavulanate 2–1 and 20–10 lgc 20–10 lg
Piperacillin 30 lg 100 lg
Piperacillin-tazobactam 30–6 lg 100–10 lg
Cefotaxime 5 lg 30 lg
Ceftaroline 5 lg 30 lg
Ceftazidime 10 lg 30 lg
Gentamicin (test for HLAR) 30 lg 120 lg
Vancomycin 5 lg 30 lg
Linezolid 10 lg 30 lg
Nitrofurantoin 100 lg 300 lg
HLAR, high-level aminoglycoside resistance.
aCeftriaxone 30 lg and cefepime 30 lg are also under consideration for lower
disk contents in the EUCAST disk diffusion test.
b2 lg for Haemophilus inﬂuenzae, Pasteurella multocida, Listeria monocytogenes,
Staphylococcus saprophyticus and streptococci.
c2–1 lg for Haemophilus inﬂuenzae, Moraxella catarrhalis and Pasteurella multocida.
TABLE 3. Comparison of EUCAST mean zone diametersa
and ‘target values’b for CLSI recommended quality control
strains
Number of antimicrobial agents/total
number of agents tested
E. coli P. aeruginosa S. aureus
ATCC 25922 ATCC 27853 ATCC 25923
≤2 mm from ‘CLSI target’ 29/29 15/15 31/31
≤1 mm from ‘CLSI target’ 24/29 10/15 30/31
=CLSI target 8/29 3/15 9/31
aEUCAST mean values were each calculated from a total of ≥20 separate tests on
MH agar from Oxoid (two batches), BBL (two batches) and bioMerieux (one
batch).
bMedian values of published CLSI control zone diameter ranges.
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tests during this time period, and inhibition zones were read by
a total of 15 different technicians. Several lots of antimicrobial
disks (≥5 per agent) were used during this time period. Of the
investigated 48 combinations of quality control strains and
antimicrobial agents, most showed excellent reproducibility
with random variation within the control range and very few
zone diameters out of range (e. g. Fig. 1). For control ranges
established by EUCAST, only four combinations had >5%
readings out of range, S. aureus ATCC 29213 with trimetho-
prim-sulphamethoxazole (5.5%), S. pneumoniae ATCC 49619
with tetracycline (5.2%) and H. inﬂuenzae NCTC 8468 with
cefotaxime (6.7%) and trimethoprim-sulphamethoxazole
(8.8%). Of these, H. inﬂuenzae with trimethoprim-sulphameth-
oxazole has been shown to be particularly sensitive to variation
in media (manufacturer and batch), presumably due to varying
content of thymidine. However, testing of clinical isolates
(n = 147) on MH-F agar prepared with MH from Oxoid and
BBL resulted in similar susceptibility categorization with only a
few minor errors for both media. For clinical isolates, annual
zone diameter distributions for 2009–2012 were very similar
for all organism-antimicrobial agent combinations tested, with
medians within 1 mm (e. g. Fig. 2).
Quality Control Criteria
Following testing of control strains as described above, EUCAST
has, when possible, adopted the CLSI criteria for quality control
strains for disk diffusion tests [11]. In cases where EUCAST
recommendations for strains, medium or disk contents are
different from those of CLSI, EUCAST has developed separate
criteria. EUCAST quality control tables list both acceptable
ranges and target values (Table 4). The targets are based on the
median value of the CLSI range and have been checked for
accuracy during the development of the EUCAST methodology
as described above. A few discrepancies between the ‘CLSI
targets’ and the EUCAST results have been identiﬁed (e.g. E. coli
ATCC 25922 with meropenem 10 lg disks and P. aeruginosa
ATCC 27853 with gentamicin 10 lg and tobramycin 10 lg
disks). When discrepancies have been conﬁrmed in tests in
multiple laboratories, some of these have been revised in
collaboration with the CLSI (e. g. P. aeruginosa with gentamicin
10 lg and tobramycin 10 lg disks) [11].
Establishment of EUCAST quality control ranges
When there were no CLSI quality control criteria, targets and
ranges were developed by EUCAST. The targets were initially
based on the mean values of 20 separate tests for each
strain-agent combination, using a total of ﬁve different batches
of MH agar from three manufacturers (two batches from
Oxoid, two from BBL and one from bioMerieux) and disks
from Oxoid. All testing was performed in parallel with testing
of the CLSI control strains as described above. EUCAST
control ranges were based on mean values 2 SD, with a
minimum range of 3 mm. All targets and ranges were
re-evaluated with additional media and disk batches from a
range of manufacturers. Control criteria were revised when
there were data to support a change, and since version 1.0 of
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FIG. 2. Reproducibility of the EUCAST disk diffusion method as
illustrated by three comparisons of annual zone diameter distributions.
For each organism-antimicrobial agent combination, the distributions
are highly reproducible with similar medians and ranges. (a) E. coli vs.
cefotaxime 5 lg. (b) S. aureus vs. cefoxitin 30 lg. (c) S. pneumoniae vs.
tetracycline 30 lg.
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the EUCAST QC tables, 11 zone diameter ranges have been
slightly modiﬁed.
Establishment of Zone Diameter
Breakpoints Calibrated to the EUCAST
Clinical MIC Breakpoints
For most antimicrobial agents, there is good correlation
between MIC values and inhibition zone diameters [8,16].
This is especially true when species-speciﬁc correlations are
calculated. The establishment of EUCAST clinical MIC
breakpoints is described elsewhere [17–19] and techniques
for establishing zone diameter breakpoint correlates have
recently been reviewed by Kronvall et al. [20]. We utilize
several of these techniques when establishing species-speciﬁc
(e.g. for S. pneumoniae and H. inﬂuenzae) or group-speciﬁc
(e.g. for Enterobacteriaceae and staphylococci) zone diame-
ter breakpoints calibrated to the EUCAST clinical MIC
breakpoints. MIC-zone diameter correlates and MIC and
zone diameter distributions were analysed. Large series of
MIC determinations and parallel disk diffusion tests (100–
1000 per organism-antimicrobial agent combination) were
performed at the EUCAST Laboratory of Antimicrobial
Susceptibility Testing in collaboration with several other
laboratories. In addition, we have had access to MIC-zone
diameter distributions produced with CLSI methodology
(courtesy of Dr R.N. Jones at JMI Laboratories, North
Liberty, Iowa, USA).
Determination of epidemiological cut-off (ECOFF) values
from wild-type MIC and zone diameter distributions
The use of wild-type MIC distributions to distinguish wild-type
isolates from those with acquired resistance mechanisms and
to establish ECOFFs has been described by Kahlmeter et al.
[7]. The MIC distributions in the EUCAST database are based
on more than 50 000 isolates for some antimicrobial
agent-organism combinations. These MIC distributions are
composed of collated data from a large number of investiga-
tors and laboratories. The zone diameter distributions, all
from tests performed with the EUCAST disk method as
described in this paper, were originally all from the EUCAST
Laboratory for Antimicrobial Susceptibility Testing, but data
from other laboratories using the EUCAST disk diffusion test
have been added subsequently. By analysis of MIC and zone
diameter distributions, we have deﬁned wild-type distributions
from which MIC and zone diameter epidemiological cut-off
values (ECOFFs) were established (e.g. Fig. 3b) [21].
Calibrating inhibition zone diameters to MIC values and/or
resistance mechanisms
The zone diameter breakpoints were established by performing
simultaneous MIC determination and disk diffusion tests on 10–
1000 isolates per species, particularly isolates with MIC values
close to EUCASTbreakpoints or inhibition zone diameters close
to the low end of the wild-type population. When establishing
EUCAST zone diameter breakpoints, MIC determination was
performed by both reference methodology (i.e. broth microdi-
lution according to the International Standards Organisation
TABLE 4. Excerpt from the EUCAST routine quality control tables version 3.0
Mueller-Hinton agar, McFarland 0.5, air, 35±1ºC, 18±2h. Read zone edges as the point showing no 
growth viewed from the back of the plate against a dark background illuminated with reflected light.
Escherichia coli ATCC 25922
(NCTC 12241, CIP 76.24, DSM 1103, CCUG 17620, CECT 434) 
Antimicrobial agent
MIC (mg/L)
Disk content (lg)
Inhibition zone diameter
(mm)
Targeta Rangeb Targeta Rangec
Amikacin 1–2 0.5–4 30 23 19–26
Cefadroxil – – 30 17 14–20
Cefotaxime 0.06 0.03–0.12 5 28 25–31
Cefoxitin 4 2–8 30 26 23–29
Ceftriaxone 0.06 0.03–0.12 30 32 29–35
Cefuroxime 4 2–8 30 23 20–26
Ciproﬂoxacin 0.008 0.004–0.015 5 35 30–40
Gentamicin 0.5 0.25–1 10 23 19–26
Meropenem 0.015–0.03 0.008–0.06 10 31 28–34
Piperacillin-tazobactam 2/4 1/4–4/4 30–6 24 21–27
Tobramycin 0.5 0.25–1 10 22 18–26
Trimethoprim 1 0.5–2 5 25 21–28
Trimethoprim-sulphamethoxazole ≤0.5/9.5b – 1.25–23.75 26 23–29
aCalculated by EUCAST.
bFrom the International Standards Organisation, ISO 20776-1: 2006, except ranges in bold/italics established by EUCAST.
cFrom the Clinical and Laboratory Standards Institute, M100-S22: 32:3, 2012, except ranges in bold/italics established by EUCAST. All ranges have been validated
by EUCAST.
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(ISO) standard [22]) and other methodologies calibrated to the
ISO method (e.g. broth microdilution with media supplemented
for fastidious organisms [23,24] and gradient MIC tests). When
possible, isolates with known resistance mechanisms (e.g.
ESBL-producing Enterobacteriaceae, Staphylococcus spp. positive
for mecA and Enterococcus spp. positive for vanA and vanB) have
been used to test the breakpoints. Correlations of MICs and
zone diameters for a wide range of organisms and antimicrobial
agents are presented on the EUCAST website in two formats.
Firstly, as zone diameter bar charts in which bars are subdivided
with each MIC value plotted in a colour representing a speciﬁc
MIC value [16] (e.g. Fig. 3a) and, secondly, asMIC-zone diameter
distributions on the zone diameter distributionwebsite [25] (e.g.
Fig. 3b). Several MIC-zone diameter distributions are the result
of collaborations with other laboratories, both within and
outside Europe. An important principle in the setting of clinical
breakpoints by EUCAST is, when possible, to avoid setting
breakpoints that divide wild-type distributions of target species
[7]. The same principle was applied to the zone diameter
breakpoints by checking breakpoints indicated by the MIC-zone
diameter correlations against zone diameter distributions for
clinical isolates [25].
EUCAST Breakpoint Tables
The EUCAST clinical breakpoint tables v 1.0, with tentative zone
diameter breakpoints, were published on the EUCAST website
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FIG. 3. Examples of MIC-zone diameter correlations for S. aureus vs. tobramycin 10 lg as used by EUCAST to determine and validate zone
diameter breakpoints. (a) Inhibition zone diameter distribution with corresponding MIC values represented as different coloured bars, as presented
on the EUCAST website http://www.eucast.org/eucast_disk_diffusion_test/calibration_and_validation/. (b) Inhibition zone diameter distribution
(aggregated clinical data from several test sites) and MIC correlates from Figure 3(a) and additional data from multiple sources, as presented in the
EUCAST MIC and zone diameter distribution database http://mic.eucast.org/Eucast2/.
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in December 2009. The breakpoint tables are revised yearly and
are published for consultation on thewebsite early in December
each year. The ﬁnalized revised version is published on 1 January
each year and contains revisions of existing breakpoints,
breakpoints for added species or new antimicrobial agents.
Should there be an urgent need for changing or adding
breakpoints during a year, these are published in an addendum.
EUCAST clinical breakpoint tables present clinical MIC break-
points expressed as S ≤ X mg/L, R > X mg/L and zone diam-
eter breakpoints expressed as S ≥ X mm, R < X mm. The
intermediate category is not spelled out and is inferred from the
susceptible and resistant breakpoints. Relevant background data
on antimicrobial agents and breakpoints, as well as relevant MIC
and zone diameter distributions, can be accessed via links in the
table on the EUCASTwebsite, where antimicrobial agent names
are linked to EUCAST rationale documents, and MIC and zone
diameter breakpoints are linked to MIC and zone diameter
distributions, respectively.
Implementation of the EUCAST Disk
Diffusion Test in Routine Clinical
Microbiology Laboratories
Changing from another method to the EUCAST standardized
disk diffusion test is not difﬁcult, but needs planning. In order
to facilitate this process, EUCAST has published an implemen-
tation guide on the EUCAST website [26]. A few important
aspects are highlighted and discussed below.
How to select and prepare Mueller–Hinton medium
MH agar may vary between manufacturers and between
batches from the same manufacturer and each batch of MH
agar used for disk diffusion testing should be tested to ensure
that inhibition zone diameters for antimicrobial agents are
within EUCAST quality control limits for agents that are used
routinely in the laboratory. Laboratories making their own
media are encouraged to obtain test samples and to ensure
that the new batch meets the quality control criteria prior to
buying a large quantity of a batch. By extensively testing a new
batch and then purchasing large quantities, the laboratory can
ensure long periods of consistent quality. Each new batch of
MH agar, disks or supplements should be tested to ensure that
inhibition zones for all antimicrobial agents that are part of
routine panels are within the acceptable ranges deﬁned in the
EUCAST quality control tables.
Agar depth and supplements for fastidious organisms must
be consistently as deﬁned for the method. The agar depth
should be 4.0  0.5 mm and systematic use of plates that are
close to the limits, particularly the lower limit, is more likely to
result in errors due to variation in medium depth. It is crucial
that the horse blood is mechanically, not chemically, deﬁbrin-
ated and it must not be lysed. Chemical deﬁbrination will result
in inhibition zone diameters out of range for some organ-
ism-antimicrobial agent combinations. For b-NAD, a purity of
≥98% should be used to ensure adequate growth of H. inﬂu-
enzae and to minimize batch-to-batch variation. Several
manufacturers provide b-NAD of required purity.
Preparation and incubation of plates
Inoculation of agar plates with the standardized organism
suspension can be performed either by hand or by using a plate
rotator. Safety regulations prohibit the use of ﬂooding, which
may result in splashing and/or production of aerosols of
concentrated bacteria. Regardless of whether plates are
inoculated by hand or by use of a rotating device, it is
important to achieve an even conﬂuent growth for all
organisms tested. For Gram-negative organisms, it is particu-
larly important to avoid over-inoculation. This is best achieved
by removing excess ﬂuid from the swab before streaking the
plates. The growth should be even over the agar surface and
jagged zone edges indicate uneven inoculation. Furthermore, it
is important not to exceed the incubation period of 16–20 h
because prolonged incubation often results in indistinct zone
edges or colonies within the inhibition zones, which might
result in reporting isolates as falsely resistant. When testing
H. inﬂuenzae, it is also important to remove excess moisture
before inoculation of plates. If condensation can be seen on the
inside of the lid, fuzzy zone edges and/or hazes within zones
are more likely to be seen with some isolates.
Reading of inhibition zones
When implementing the EUCAST disk diffusion test, training in
the reading of zones is essential to ensure consistent reading
between technologists. This is best achieved by introducing
regular exercises where all laboratory staff read inhibition zones
from the same plate with EUCAST quality control strains. The
mean and variation of all readings can be compared with the
target values and the ranges published in the quality control
tables [15]. From experiments performed with staff in routine
laboratories we know that standardized reading to within
1 mm can be achieved among 15–20 technologists. The
quality of reading can furthermore be assessed by comparing
the ranges and medians of in-house zone diameter distributions
(n ≥ 50) for routine clinical isolates with those published by
EUCAST [25]. For wild-type isolates, the median and width of
the in-house distribution should match that of the EUCAST
distribution.Wild-type distributions with a median that deviates
more than 2 mm from the EUCAST target clearly indicate a
systematic difference between the in-house and the recom-
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mended method. Wild-type distributions that are wider than
the reference distribution are normally the result of variation in
reading of zones among staff. This is also likely to be the reason
for irregular wild-type distributions. The EUCAST reading guide
[13] contains speciﬁc instructions and illustrative pictures and is
recommended for use during implementation of the EUCAST
disk diffusion test and also for continued education of staff.
Routine quality control
Several factors affect inhibition zone sizes, including themedium,
preparation of agar plates, inoculum density, age of colonies,
quality of disks, incubation temperature, incubation time and
reading of zone diameters [1,8,9]. Variations in zone diameters
can be due to either in-house factors, such as inadequate
training, inconsistency in reading results or inadequate control
of equipment or reagents, or to external factors such as variation
between batches of media or disks. Variation caused by a change
in medium or other reagents should have been detected by
testing before these were accepted for routine use. Strictly
controlling the in-house variation provides conﬁdence when
diagnosing and dealing with external reasons for variation. The
EUCAST Laboratory for Antimicrobial Susceptibility Testing in
V€axj€o may be contacted for assistance in investigation of the
cause of unexplained variation.
Repeat testing of EUCAST control strains as part of
consecutive daily or weekly quality control can be expected to
yield individual values randomly distributed within the recom-
mended range and with a mean within 1 mm of the EUCAST
target if the number of tests is ≥10. A systematic deviation of
the mean value, above or below the target for several agents,
should be investigated. Guidelines for investigation of quality
control results out of range or changes in trends over time are
available in the EUCAST disk diffusion test manual [12].
The ranges for the quality control strains are set to
accommodate some variation between media and disks and
repeated testing of quality control strains is sometimes not
sufﬁcient to detect speciﬁc problems [27], which may be
detected by comparison of results with reference distribu-
tions. Comparison of the median and range of zone diameter
distributions from a laboratory with the reference distribu-
tions available on the EUCAST website [25] can be more
effective than testing of quality control strains for detection of
systematic errors, or problems with disks or media, as well as
problems with speciﬁc organism-antimicrobial agent combina-
tions. Examples are shown in Fig. 4, where zone diameter
distributions from 17 Swedish laboratories are compared with
the EUCAST reference distribution. The highlighted distribu-
tion is from a laboratory with excellent reproducibility but
with a systematic deviation from the reference distribution.
Systematic differences in median values compared with the
reference distributions will result in erroneous susceptibility
categorization, especially for organism-antimicrobial agent
combinations where there are resistant isolates with zone
diameters close to the susceptible zone diameter breakpoint.
The Future of the EUCAST Disk Diffusion
Test
Since 2011, more and more countries, mainly in Europe, have
adopted the EUCAST clinical breakpoints and the EUCAST disk
diffusion test. EUCAST encourages laboratories with expertise
in susceptibility testing to participate in a network of collabo-
rating laboratories interested in contributing to the develop-
ment and maintenance of the disk diffusion test. With this
network, the ﬁnancial support of the European Society of
Clinical Microbiology and Infectious Diseases (ESCMID) and the
support and interest of National Antimicrobial Susceptibility
Testing Committees (NACs), the future of the EUCAST disk
diffusion method is secured. Automated susceptibility testing
may relieve laboratories of some AST work, but their lack of
versatility, the unavailability of some agents and tests for some
species, and their long development times, still favour the use of
disk diffusion testing for many years to come. All documents and
data on the EUCAST website are freely available.
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